XML 59 R53.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 28, 2024
USD ($)
Sep. 05, 2023
USD ($)
Jun. 30, 2022
USD ($)
Sep. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Mar. 22, 2024
Item
Dec. 31, 2023
USD ($)
Oct. 09, 2023
Item
Loss Contingencies [Line Items]                      
Reimbursable research and development costs from a collaboration partner                   $ 1,491,000  
Research and development       $ 33,226,000   $ 19,453,000 $ 92,218,000 $ 60,268,000      
Senior Secured Loan Facility                      
Loss Contingencies [Line Items]                      
Term of loan agreement   4 years                  
Aggregate principal amount   $ 50,000,000                  
Amount available for draw down, Lenders discretion       25,000,000     25,000,000        
Interest rate   8.00%                  
Incremental interest rate at the event of default   3.00%                  
Unused commitment fee percentage   1.50%                  
Amendment of Original Loan Agreement                      
Loss Contingencies [Line Items]                      
Aggregate principal amount $ 100,000,000                    
Amount currently available for draw down 25,000,000                    
Amount available for draw down upon achieving certain milestones related to execution of first line pivotal phase 3 25,000,000                    
Amount available for draw down, Lenders discretion $ 50,000,000                    
Maturity date Jul. 01, 2028                    
Novartis Agreement                      
Loss Contingencies [Line Items]                      
Number of patients | Item                 15   60
Novartis Agreement | Bio Medical Research Inc                      
Loss Contingencies [Line Items]                      
Reimbursable research and development costs from a collaboration partner       0     $ 0        
Aurigene Agreement                      
Loss Contingencies [Line Items]                      
Milestone payments to be paid to collaborative partner     $ 60,000,000                
Upfront payment, research and development.     8,000,000                
Research and development       $ 0 $ 5,000,000            
Aurigene Agreement | Commercial Milestone                      
Loss Contingencies [Line Items]                      
Milestone payments to be paid to collaborative partner     $ 370,000,000